Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 34Terminated 8Active not recruiting 6Recruiting 3Withdrawn 1Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 381Breast Neoplasms 364Colorectal Neoplasms 238Stomach Neoplasms 218Carcinoma, Hepatocellular 155Lung Neoplasms 123Neoplasms 120Pancreatic Neoplasms 109Prostatic Neoplasms 100Neoplasm Metastasis 96Recurrence 95Rectal Neoplasms 95Ovarian Neoplasms 90Nasopharyngeal Carcinoma 88Esophageal Neoplasms 82Esophageal Squamous Cell Carcinoma 81Lymphoma, Large B-Cell, Diffuse 79Melanoma 75Small Cell Lung Carcinoma 71Uterine Cervical Neoplasms 70Lymphoma 70Leukemia, Myeloid, Acute 70Brain Neoplasms 69Sarcoma 68Head and Neck Neoplasms 68Squamous Cell Carcinoma of Head and Neck 67Multiple Myeloma 65Carcinoma, Renal Cell 63Triple Negative Breast Neoplasms 61Lymphoma, Non-Hodgkin 53

Interventions

Sunitinib 1Immunohistochemistry 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Unknown × Urethral Neoplasms × Clear all
NCT01118039 2013-08-07

Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
41 enrolled
Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡